A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

NCT06794268 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

BIOLOGICAL: Lisocabtagene maraleucel

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company